CAMP4 Therapeutics Corporation Operating Cash Flow
CAMP4 Therapeutics Corporation (CAMP) reported Operating Cash Flow of -$23.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- CAMP4 Therapeutics Corporation net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$12.69M.
- CAMP4 Therapeutics Corporation net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$10.98M.
- CAMP4 Therapeutics Corporation net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $6.29M.
- CAMP4 Therapeutics Corporation net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$11.22M.
- CAMP4 Therapeutics Corporation net cash provided by (used in) operating activities for fiscal 2025 was -$29.55M.
- CAMP4 Therapeutics Corporation net cash provided by (used in) operating activities for fiscal 2024 was -$45.56M.
- CAMP4 Therapeutics Corporation net cash provided by (used in) operating activities for fiscal 2023 was -$44.16M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$23.67M 10-Q · filed 2026-08-13 | -$17.37M derived: sum of 3 quarters · filed 2026-08-13 | -$28.59M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$10.98M 10-Q · filed 2026-05-07 | -$4.69M derived: sum of 2 quarters · filed 2026-05-07 | -$15.90M derived: sum of 3 quarters · filed 2026-05-07 | -$26.25M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $6.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$4.92M derived: sum of 2 quarters · filed 2026-03-05 | -$15.27M derived: sum of 3 quarters · filed 2026-08-13 | -$29.55M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$11.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$21.56M derived: sum of 2 quarters · filed 2026-08-13 | -$35.85M 10-Q · filed 2025-11-06 | -$47.13M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$10.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$24.63M 10-Q · filed 2026-08-13 | -$35.92M derived: sum of 3 quarters · filed 2026-08-13 | -$45.61M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$14.29M 10-Q · filed 2026-05-07 | -$25.57M derived: sum of 2 quarters · filed 2026-05-07 | -$35.27M derived: sum of 3 quarters · filed 2026-05-07 | -$48.70M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$11.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$20.98M derived: sum of 2 quarters · filed 2026-03-05 | -$34.42M derived: sum of 3 quarters · filed 2026-03-05 | -$45.56M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$9.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$23.13M derived: sum of 2 quarters · filed 2025-11-06 | -$34.27M 10-Q · filed 2025-11-06 | -$46.06M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$13.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$24.58M 10-Q · filed 2025-08-14 | -$36.36M derived: sum of 3 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$11.14M 10-Q · filed 2025-05-13 | -$22.93M derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$11.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$44.16M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | -$32.37M 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |